BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29048622)

  • 1. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
    Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
    Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
    Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
    Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dclk1 Inhibition Cancels 5-FU-induced Cell-cycle Arrest and Decreases Cell Survival in Colorectal Cancer.
    Suehiro Y; Takemoto Y; Nishimoto A; Ueno K; Shirasawa B; Tanaka T; Kugimiya N; Suga A; Harada E; Hamano K
    Anticancer Res; 2018 Nov; 38(11):6225-6230. PubMed ID: 30396941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
    Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
    Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
    Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
    Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
    Zhao H; Duan Q; Zhang Z; Li H; Wu H; Shen Q; Wang C; Yin T
    J Cell Mol Med; 2017 Sep; 21(9):2055-2067. PubMed ID: 28244691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
    Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
    Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells].
    Yan R; Liang ZW; Liu HS; Ge Y; An GY
    Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):594-604. PubMed ID: 37462016
    [No Abstract]   [Full Text] [Related]  

  • 10. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.
    Dandawate P; Ghosh C; Palaniyandi K; Paul S; Rawal S; Pradhan R; Sayed AAA; Choudhury S; Standing D; Subramaniam D; Padhye SB; Gunewardena S; Thomas SM; Neil MO; Tawfik O; Welch DR; Jensen RA; Maliski S; Weir S; Iwakuma T; Anant S; Dhar A
    Gastroenterology; 2019 Dec; 157(6):1646-1659.e11. PubMed ID: 31442435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
    Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
    Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.
    Sureban SM; May R; Qu D; Weygant N; Chandrakesan P; Ali N; Lightfoot SA; Pantazis P; Rao CV; Postier RG; Houchen CW
    PLoS One; 2013; 8(9):e73940. PubMed ID: 24040120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
    Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2020 May; 122(10):1486-1495. PubMed ID: 32203220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.
    Nagano H; Tomimaru Y; Eguchi H; Hama N; Wada H; Kawamoto K; Kobayashi S; Mori M; Doki Y
    Int J Oncol; 2013 Oct; 43(4):1066-72. PubMed ID: 23900458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
    Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
    Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
    Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
    Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
    Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
    Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
    Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.